SHAMIR NACHUM purchased $82K of MDWD
SHAMIR NACHUM purchased 5,825 shares of MediWound Ltd. (MDWD) at $14.00 on 2026-06-03.
MediWound Ltd.
No enriched coverage for $MDWD in the last 7 days.
No SEC Form 4 filings for $MDWD in the last 30 days.
See all $MDWD insider activity →SHAMIR NACHUM purchased 5,825 shares of MediWound Ltd. (MDWD) at $14.00 on 2026-06-03.
SHAMIR NACHUM purchased 175 shares of MediWound Ltd. (MDWD) at $13.98 on 2026-06-03.
Fox David Morton purchased 1,797 shares of MediWound Ltd. (MDWD) at $14.00 on 2026-06-01.
Recent MDWD coverage spans insider activity and financial news.
Insider open-market buying can modestly support sentiment, but the disclosure is not a fundamental catalyst by itself.
Insider buying is a modest bullish signal, but this small, single-tranche purchase is unlikely to drive a large fundamental repricing by itself.
Insider open-market buying can be a modest bullish signal, but it is not a fundamental catalyst by itself.
Insider buying is a mild positive signal, but the small dollar amount limits near-term price impact.
Insider open-market buying is a modest positive signal, but the disclosure is unlikely to drive a large repricing by itself.
alphai scores every news story that mentions MDWD with an AI model for sentiment and relevance, and aggregates insider trades from MediWound Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SHAMIR NACHUM purchased 5,825 shares of MediWound Ltd. (MDWD) at $14.00 on 2026-06-03.
1 min readSHAMIR NACHUM purchased 175 shares of MediWound Ltd. (MDWD) at $13.98 on 2026-06-03.
2 min readFox David Morton purchased 1,797 shares of MediWound Ltd. (MDWD) at $14.00 on 2026-06-01.
2 min readFox David Morton purchased 10 shares of MediWound Ltd. (MDWD) at $14.23 on 2026-06-01.
2 min readFox David Morton purchased 1,730 shares of MediWound Ltd. (MDWD) at $14.22 on 2026-06-01.
2 min readRubinstein Samuel purchased 150 shares of MediWound Ltd. (MDWD) at $14.33 on 2026-05-29.
1 min readMediWound (MDWD) delivered earnings and revenue surprises of +70.37% and -15.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readOngoing Enrollment Continues in VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers ...
4 min readMediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for ...
2 min readMediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
2 min read